Agomab bags $114 million in thriving regenerative medicine sector
The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million…
The Belgian company Agomab Therapeutics has topped up its Series B round by $40.5 million…
US regulators have approved the first-in-class drug efgartigimod for the treatment of the rare muscle…
Here’s a list of the public European biotech companies that are worth more than a…
Stock markets worldwide have experienced painful instability in the last few months. As a result,…
As we enter 2021, the biotech industry is already bustling with activity. Here’s a list…
The Dutch biotech argenx has cashed in on recent positive phase III results by launching…
The Dutch biotech argenx aims to apply for FDA approval of its lead candidate efgartigimod…
The Dutch biotech argenx, which develops antibody drugs to treat autoimmune diseases and cancer, has…
The Belgian biotech AgomAb has raised €21M and partnered with the Dutch biotech argenx to…
Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The…
Belgian biotech Argenx raised over €250M in public investment on the Nasdaq Stock Market after…
Argenx has smashed its target of $150M for its US offering, which will support its cancer…